Every biotech startup hits the same wall. You've got brilliant scientists, groundbreaking science, and investors who expect results yesterday. The last thing anyone wants to think about is training infrastructure. It feels like bureaucracy, like something big pharma does because they have entire departments with nothing better to do.
Then the first FDA inspection happens, and suddenly everyone wishes they'd started building six months earlier.
I've helped build training programs at companies ranging from 50-person startups to global manufacturers. The startups are always the hardest, not because the work is more complex, but because the margin for error is essentially zero. You don't get second chances when your first commercial product depends on getting this right.
The Startup Training Paradox
Move Fast and Build Things (That Actually Work)
Startups live in a state of permanent urgency. Clinical timelines are aggressive. Investor milestones are non-negotiable. Every week spent on infrastructure feels like a week not spent on getting your therapy to patients.
So training gets pushed to the back of the line. The reasoning goes something like this: "We'll hire experienced people from big pharma. They already know GMP. We'll build the formal program later." This sounds reasonable. It isn't.
Experienced hires bring expertise, but they also bring assumptions shaped by the specific systems, cultures, and processes of their previous employers. Without a unifying training framework, you end up with a manufacturing floor where everyone is competent individually but operating from different playbooks. That's not a team. That's a collection of freelancers sharing a cleanroom.
The "We'll Do It Later" Fallacy
Later never comes. Or rather, it comes in the form of a pre-approval inspection where FDA asks to see your training program and you're suddenly assembling one from spare parts while trying to look calm.
I've seen this scenario play out repeatedly. A startup reaches the point where they need a functioning training system (usually about six months before they expected to need it), and they realize that building retroactively is exponentially harder than building as you go. All the tribal knowledge that accumulated during the early days? It's locked in people's heads, and those people are too busy running manufacturing operations to stop and document anything.
The Resource Equation
Big pharma can dedicate teams of people to training program development. A startup might have one person splitting their time between training, quality assurance, and whatever else needs doing that week. The challenge isn't just building a training program. It's building one that's sustainable with minimal dedicated resources.
This constraint actually leads to better design decisions, if you approach it correctly. When you can't throw headcount at the problem, you're forced to build systems that are efficient, modular, and maintainable. Some of the best training architectures I've seen came from startups that didn't have the luxury of overengineering.
What to Build First (And What Can Wait)
Phase 1: The Non-Negotiable Foundation
Before your first GMP manufacturing run, you need four things in place. Not perfect, but functional and documented.
A training matrix. This maps every role in your organization to the specific training requirements for that role. It doesn't need to be elaborate. A well-structured spreadsheet works fine at this stage. What matters is that you can answer the question: "For any given person, what training do they need, and have they completed it?"
GMP fundamentals training. Every person who enters your manufacturing facility needs a baseline understanding of GMP principles. This includes gowning procedures, documentation practices, contamination control basics, and reporting requirements. Build this once, deliver it consistently, and update it when regulations change.
Role-specific SOPs with training assessments. For each manufacturing role, you need procedures that describe what the person does and assessments that verify they can do it. Start with your most critical processes, the ones where errors have the highest impact on product quality or patient safety.
A training record system. This can be as simple as a controlled spreadsheet or as sophisticated as a learning management system. The key requirement is that you can produce, at any time, documentation showing who was trained on what, when, and how their competency was verified. If you can't produce this during an inspection, nothing else matters.
Phase 2: Building Depth
Once the foundation is in place and your first manufacturing campaigns are running, you can start building depth. This includes competency-based assessments that go beyond "read and sign" training, documented on-the-job training programs with qualified trainers, deviation and CAPA investigation training for your quality team, and cross-training programs that build operational resilience.
The timing of Phase 2 depends on your regulatory pathway and manufacturing complexity. For cell and gene therapy companies, where processes are inherently variable and operator judgment is critical, I'd push for earlier implementation. For more standardized manufacturing, you have slightly more runway.
Phase 3: Maturation
This is where your training program stops being a compliance requirement and starts being a competitive advantage. Training effectiveness metrics tied to manufacturing outcomes. Continuous improvement cycles driven by deviation trends and operator feedback. Leadership development programs that build your next generation of manufacturing managers from within.
Most startups don't reach Phase 3 until they're no longer really startups. And that's fine. The goal isn't to build a perfect system on day one. The goal is to build a system that's good enough to keep you compliant and flexible enough to grow with you.
Common Mistakes (And How to Avoid Them)
Mistake: Copying Big Pharma's Homework
The temptation is enormous. Your VP of Manufacturing came from a large pharma company with a mature training program. They have templates, curricula, and assessment tools from their previous employer. Why not just adapt those?
Because a training program designed for a 2,000-person manufacturing site with dedicated training staff, an established LMS, and 20 years of institutional knowledge will collapse under its own weight at a 50-person startup. The administrative burden alone will overwhelm your limited resources, and operators will spend more time on training paperwork than actual training.
Borrow principles, not programs. Understand why big pharma does what it does, then design something that achieves the same regulatory objectives with a fraction of the overhead.
Mistake: Treating Training as a Quality System Afterthought
I've watched startups build out their deviation management system, their CAPA process, their document control infrastructure, and their change control procedures, all before giving serious thought to training. This is backwards.
Training is the system that makes all the other systems work. Your deviation management process is only as good as the people executing it. Your CAPA effectiveness depends on whether people understand root cause analysis. Your document control system fails if people don't know how to write or follow procedures.
Build training in parallel with your other quality systems, not after them.
Mistake: Over-Investing in Technology Too Early
You do not need a six-figure learning management system when you have 30 employees. You need a system you can actually manage and maintain with the resources you have. I've seen startups purchase enterprise LMS platforms, spend months configuring them, and then abandon them because nobody had time to keep the content current.
Start simple. Use tools your team already knows. A well-organized SharePoint site or controlled Google Drive with clear naming conventions and version control will serve you better than an expensive LMS that nobody maintains.
Invest in technology when your manual systems start breaking down, which usually happens somewhere between 75 and 150 employees. By then you'll know exactly what you need, because you'll know exactly what your current system can't handle.
Mistake: Ignoring the Culture Component
Training programs don't exist in a vacuum. They exist within a culture that either values learning or treats it as a compliance checkbox. At a startup, that culture gets established early and is very difficult to change later.
If leadership treats training as an interruption to "real work," operators will too. If training completion is celebrated with the same enthusiasm as hitting manufacturing milestones, people will take it seriously. This isn't about motivational posters. It's about whether leadership actually allocates time for training, participates in it themselves, and treats training failures as systemic issues rather than individual performance problems.
The Cell and Gene Therapy Factor
Why CGT Startups Face Unique Challenges
Cell and gene therapy manufacturing adds a layer of complexity that traditional pharma training programs aren't designed to handle. Processes are often patient-specific, which means operators need to understand not just what to do but why each step matters for that specific batch. The margin for error in autologous manufacturing, where you can't rerun a patient's cells, is essentially zero.
Operator judgment becomes a critical quality attribute. Unlike traditional pharma where processes are highly automated and standardized, CGT manufacturing often requires real-time decisions based on how cells are behaving. Training for this kind of work needs to go well beyond procedure compliance. It needs to build genuine understanding.
Building Competency, Not Just Compliance
For CGT companies, the gap between "trained" and "competent" can be the difference between a successful therapy and a lost batch. Competency assessment needs to include scenario-based evaluations where operators demonstrate judgment under realistic conditions. What do you do when cells aren't expanding as expected? When contamination indicators are borderline? When equipment malfunctions mid-process?
These situations can't be trained through documents alone. They require hands-on experience, structured mentoring, and assessment methods that evaluate decision-making quality, not just procedure adherence.
The Bottom Line
Building a training program at a biotech startup isn't about replicating what big pharma does on a smaller scale. It's about building something purpose-fit: compliant enough to satisfy regulators, practical enough to actually work with limited resources, and flexible enough to scale as you grow.
Start with the non-negotiables. Build depth when your operations demand it. Invest in technology when your manual systems can't keep up. And above all, treat training as a foundational system that enables everything else, not an afterthought that gets bolted on at the last minute.
The startups that get training right early don't just survive inspections. They build organizations that can scale without breaking.